Jens Benn Sørensen

11PUBLICATIONS
22CO-AUTHORS
Gene and molecular therapyMolecular targetsMedical biotechnology diagnostics (incl. biosensors)Solid tumoursCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Jul 11, 2026
Targeting MET amplification in non-small cell lung cancer: encouraging results with vebreltinib from the phase II KUNPENG study.

|Jun 17, 2026
Are lazertinib and osimertinib comparable for treating advanced EGFR-mutant non-small cell lung cancer?-insights and limitations from the MARIPOSA study.

|Jan 10, 2026
Improvement of Diagnostics in NSCLC Patients with MET Exon 14 Mutations Using Complementary DNA/RNA-NGS and Identification of Two Novel Exonic Splicing Mutations.

Edyta Maria Urbanska, Thomas Koed Doktor, Linea Cecilie Melchior

|Jul 12, 2025
Refining Criteria for Choosing the First-Line Treatment for Real-World Patients with Advanced ALK-Rearranged NSCLC.

Edyta Maria Urbanska, Peter Rindom Koffeldt, Morten Grauslund

|Mar 21, 2025
Alectinib impressively enters the adjuvant setting for early-stage ALK-rearranged non-small cell lung cancer and outperforms chemotherapy-let's define who benefits the most.

Eric Santoni-Rugiu, Jens Benn Sørensen, Edyta Maria Urbanska

|Oct 21, 2024
ALK-tyrosine kinase inhibitor intrinsic resistance due to de novo MET-amplification in metastatic ALK-rearranged non-small cell lung cancer effectively treated by alectinib-crizotinib combination-case report.

Edyta M Urbanska, Morten Grauslund, Siv M S Berger

Pageof 2

Frequent Collaborators

7 joint publications

Eric Santoni-Rugiu

6 joint publications

Edyta Maria Urbanska

4 joint publications

Morten Grauslund

3 joint publications

Peter Rindom Koffeldt